On June 22 of this year, Keji Pharmaceuticals' Kailimei was approved for domestic marketing as the world's first CAR-T cell product to treat solid tumors, but the price was as high as 990,000 yuan. How many patients would actually be willing to pay for it? With the disclosure of the company's semi-annual report, the issue received investors' attention. On the morning of August 19, Keji Pharmaceutical said at the performance conference that Kailimei has prescribed the country's first clinical prescription at Beijing Gaobo Hospital, the Zhongshan Hospital affiliated to Fudan University has completed the world's first cell collection from patients, and the Jiahui International Oncology Center has completed the first T-cell collection from registered patients. The drug will begin to confirm revenue in the second half of the year. Keji Pharmaceutical expects Kailimei's sales peak in mainland China to reach more than 2 billion yuan, and it is expected to receive 200 treatments in 2026.

On June 22 of this year, Keji Pharmaceuticals' Kailimei was approved for domestic marketing as the world's first CAR-T cell product to treat solid tumors, but the price was as high as 990,000 yuan. How many patients would actually be willing to pay for it? With the disclosure of the company's semi-annual report, the issue received investors' attention. On the morning of August 19, Keji Pharmaceutical said at the performance conference that Kailimei has prescribed the country's first clinical prescription at Beijing Gaobo Hospital, the Zhongshan Hospital affiliated to Fudan University has completed the world's first cell collection from patients, and the Jiahui International Oncology Center has completed the first T-cell collection from registered patients. The drug will begin to confirm revenue in the second half of the year. Keji Pharmaceutical expects Kailimei's sales peak in mainland China to reach more than 2 billion yuan, and it is expected to receive 200 treatments in 2026.